Provided by Tiger Trade Technology Pte. Ltd.

Oncolytics Biotech Inc

0.8431
+0.04145.16%
Post-market: 0.8300-0.0131-1.55%19:58 EDT
Volume:544.36K
Turnover:447.50K
Market Cap:107.50M
PE:-2.62
High:0.8492
Open:0.8000
Low:0.8000
Close:0.8017
52wk High:1.51
52wk Low:0.7301
Shares:127.51M
Float Shares:122.97M
Volume Ratio:0.73
T/O Rate:0.44%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.3215
EPS(LYR):-0.3000
ROE:-10187.64%
ROA:-211.24%
PB:-17.43
PE(LYR):-2.81

Loading ...

Oncolytics Gets US Patent for Pelareorep Manufacturing Process

MT Newswires Live
·
Jun 16

Oncolytics secures new patent for pelareorep manufacturing

TIPRANKS
·
Jun 16

Oncolytics Biotech wins new US manufacturing patent for pelareorep, protection through 2044

Reuters
·
Jun 16

Oncolytics Biotech - Announces New U.S. Patent for Pelareorep Manufacturing Process

THOMSON REUTERS
·
Jun 16

Oncolytics Biotech COO John Bearden McAdory files initial beneficial ownership statement

Reuters
·
Jun 04

Oncolytics Biotech director Stephen C. Glover files initial beneficial ownership statement

Reuters
·
Jun 04

Oncolytics promotes John McAdory to COO

TIPRANKS
·
Jun 02

Oncolytics Biotech® Announces Appointment of Steve Glover to Board of Directors and Promotion of John Mcadory to Chief Operating Officer

THOMSON REUTERS
·
Jun 02

Oncolytics announces initial data from pelareorep combination study

TIPRANKS
·
Jun 01

Oncolytics Says Preclinical Results Back Further Evaluation of Pelareorep Plus RAS-Targeted Approaches

MT Newswires Live
·
Jun 01

Oncolytics Biotech reports positive preclinical data for pelareorep with RAS-targeted therapies in solid tumor model

Reuters
·
Jun 01

Oncolytics Biotech to present data at ASCO 2026 on pelareorep

TIPRANKS
·
May 22

Oncolytics Biotech presents ASCO 2026 data from pelareorep trials in GI tumors

Reuters
·
May 22

Oncolytics net loss more than doubled to $9.24 million in Q1 2026

Reuters
·
May 15

Lake Street Sticks to Its Buy Rating for Oncolytics Biotech (ONCY)

TIPRANKS
·
May 05

BRIEF-Oncolytics Biotech® Reports Durable Responses In Second-Line Ras-Mutant Mss Colorectal Cancer

Reuters
·
May 04

Oncolytics says pelareorep combo shows 19.5-month response duration in Phase 2 mCRC study

Reuters
·
May 04

Oncolytics Biotech Inc - 2L Kras-Mutant Mss Mcrc Demonstrates 3-4X Improvement in Duration of Response VS. Historical 4-6 Month Benchmark

THOMSON REUTERS
·
May 04

Oncolytics Biotech Inc - Pelaeoreorep Combination Shows 19.5-Month Median Duration of Response in 2L Kras-Mutant Mss Mcrc

THOMSON REUTERS
·
May 04

Oncolytics Biotech Inc - Engaged With FDA on Accelerated Approval Pathway for 2L Ras-Mutant Mss Mcrc

THOMSON REUTERS
·
May 04